Press releases

Approval should bring a new treatment option to the millions of women who suffer from uterine fibroids.

CABARNET clinical trial to evaluate the benefits of stenting in conjunction with embolic protection to treat carotid artery disease.

"We are very pleased with the enthusiasm with which the TAXUS system has been received, particularly the positive physician feedback," said Jim Tobin, President and Chief Executive Officer

Approval of paclitaxel-eluting coronary stent system marks a breakthrough event for the treatment of cardiovascular disease in the United States.

Kerkrade site will house Company's new distribution center serving European, Japanese and Inter-Continental markets.

A live webcast and replay of the March 3 session will be available.

“We plan to compete vigorously and successfully in the coronary stent market, and we have every intention of becoming, and remaining, the global leader in that market,” said Jim Tobin, President and Chief Executive Officer.

All pending disputes between the companies will be immediately dismissed; companies have also agreed to cross license patents in certain specified technology areas.

Cameron is developing a next-generation implantable cardioverter defibrillator (ICD) for the cardiac rhythm management market.

Represents a first-of-its-kind treatment option in Canada for carotid artery disease

Companies intend to continue a pre-existing collaboration in the development of less-invasive surgical tools for the treatment of arrhythmias, particularly atrial fibrillation.

Analyst meeting on Monday, February 23 will focus on the Company's outlook for 2004 and beyond.

New 120,000 square-foot building at the Maple Grove campus will house primarily research and development laboratories and offices.

Site will initially serve as the new headquarters for the Company's growing Endosurgery group.

FDA team indicated it intends to recommend approval to manufacture the TAXUS™ Express2™ paclitaxel-eluting coronary stent system for the U.S. market.

ARRIVE registry will collect and analyze "real-world" safety and clinical outcomes data for the TAXUS™ Express2™ paclitaxel-eluting stent system.

United States District Court for the District of Delaware has scheduled a trial for June 2005.

Approval will enable patients to be treated with the TAXUS stent system in private clinics and hospitals; product was previously available in France primarily through public hospitals.

A live webcast and replay of the February 3 session will be available. Learn how to tune in.

A replay of the February 2 conference call will also be available. Learn how to tune in.

A live webcast and replay of the January 27 conference session will be available.

Landmark BEACH trial to evaluate the benefits of stenting - in conjunction with embolic protection - to treat carotid artery disease.

A live webcast and replay of the January 13 conference session will be available.